Which class of antidiabetic drugs does Sitagliptin belong to?

Sitagliptin (Sitagliptin) belongs to the drug class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which is a class of oral hypoglycemic drugs used to treat type 2 diabetes.

Type 2 diabetes is a chronic metabolic disease, one of which is characterized by insulin deficiency or insulin resistance, leading to elevated blood sugar in the body. DPP-4 inhibitor is a new type of oral hypoglycemic drug. Its mechanism of action is mainly to regulate blood sugar levels by inhibiting the activity of DPP-4 enzyme.

DPP-4enzyme is an enzyme that exists on the surface of many cells in the body. Its main function is to break down glucagon (GLP-1) and insulin-like growth factor -1 (IGF-1). These two hormones play an important role in regulating blood sugar levels in the body. GLP-1It helps lower blood sugar levels by promoting the secretion of insulin and inhibiting the release of glucagon. DPP-4Inhibitors work by inhibiting the activity of DPP-4 enzymes, delaying the degradation of these two hormones, thereby increasing their concentrations in the body, thereby increasing the effect of insulin and slowing down the release of glucagon to regulate blood sugar levels.

Sitagliptin is one of the first DPP-4 inhibitors approved for marketing. Through this mechanism, it can effectively help patients with type 2 diabetes lower their blood sugar levels. One of the advantages of sitagliptin is that it is administered orally, which improves patient convenience and reduces the burden of insulin injections.

In clinical practice, DPP-4 inhibitors are usually used as monotherapy or in combination with other oral hypoglycemic drugs, insulin, etc., to achieve better blood sugar control. This treatment strategy allows patients to choose the treatment plan that best suits them based on their individual circumstances and the progression of their disease.